IN THE CLAIMS

Please cancel claims 1-9, 11 and 13-17. Please amend claims 10 and 12, and add new claims 18-31 as follows:

10. (AMENDED) A vaccine useful in inducing immune protection against arthritogenic peptides in a host comprising a recombinant gene expression vector which encodes bacterial dnaJp1 peptide having the amino acid sequence of SEQ ID NO:4.

12. (AMENDED) A method useful in inducing immune protection against arthritogenic peptides in a host comprising administering a vaccine according to claim 10 [recombinant gene expression vector which encodes dnaJp1 peptide] to the host for expression in an immunologically effective amount of dnaJp1 peptide in the host.

18. (NEW) The vaccine of claim 10, wherein the recombinant gene expression vector further encodes at least one dnaJ polypeptide other than dnaJp1 peptide.

19. (NEW) The vaccine of claim 18, wherein the dnaJ polypeptide is found in a human dnaJ protein.

20. (NEW) The vaccine of claim 10, further comprising a recombinant gene expression vector which encodes at least one dnaJ polypeptide other than dnaJp1 peptide.

21. (NEW) The vaccine of claim 20, wherein the dnaJ polypeptide is found in a human dnaJ protein.

22. (NEW) The vaccine of claim 10, wherein the dnaJp1 peptide is produced by bacteria selected from at least one of the genera consisting of *Escherichia, Lactococcus, Klebsiella, Proteus,* and *Salmonella.*

23. (NEW) The vaccine of claim 10, further comprising an immunostimulatory compound.

24. (NEW) The vaccine of claim 23, wherein the immunostimulatory compound is TGF-α.

25. (NEW) The method of claim 12, wherein the recombinant gene expression vector further encodes at least one dnaJ polypeptide other than dnaJp1 peptide.

26. (NEW) The method of claim 25, wherein the dnaJ polypeptide is found in a human dnaJ protein.

27. (NEW) The method of claim 25, wherein the vaccine further comprising a recombinant gene expression vector which encodes at least one dnaJ polypeptide other than dnaJp1 peptide.

28. (NEW) The method of claim 27, wherein the dnaJ polypeptide is found in a human dnaJ protein.

29. (NEW) The method of claim 12, wherein the dnaJp1 peptide is produced by bacteria selected from at least one of the genera consisting of *Escherichia, Lactococcus, Klebsiella, Proteus,* and *Salmonella.*

30. (NEW) The method of claim 12, wherein the vaccine further comprises an immunostimulatory compound.

31. (NEW) The method of claim 30, wherein the immunostimulatory compound is TGF-α.

REMARKS

Prior to a first Office Action in this application, Applicants request that original claims claims 1-9, 11 and 13-17 be canceled, that claims 10 and 12 be amended, and that add new claims 18-31 be added. These amendments and new claims do not involve any new matter or objectionable changes. The amendments to claims 10 and 12 track the claim language deemed allowable in the parent applications, and the new claims parallel dependent claims deemed allowable in the parent applications. When the Examiner takes this application up for action, she is requested to take the foregoing into account.